Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cloperastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.97 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.97 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.64 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cloperastine SCHEMBL29617329 | 0.99 | SLC6A2 (1.00) | CYP3A4SLC6A2SLC6A4SLC6A3CYP1A2 | |
| Cloperastine SCHEMBL9613613 | 0.99 | SLC6A2 (1.00) | CYP3A4SLC6A2SLC6A4SLC6A3CYP1A2 | |
| Cloperastine SCHEMBL284715 | 0.99 | SLC6A2 (1.00) | CYP3A4SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL1151981 | 0.97 | SLC6A2 (0.97) | CYP3A4SLC6A2SLC6A4SLC6A3CYP1A2 | |
| Cloperastine SCHEMBL1651228 | 0.96 | SLC6A2 (0.95) | CYP3A4SLC6A2SLC6A4SLC6A3CYP1A2 | |
| Perastine SCHEMBL29768269 | 0.91 | CYP3A4 (0.83) | CYP3A4SLC6A2SLC6A4SLC6A3CYP1A2 | |
| Perastine SCHEMBL1506306 | 0.90 | CYP3A4 (0.83) | CYP3A4SLC6A2SLC6A4SLC6A3CYP1A2 | |
| Cloperastine SCHEMBL20764783 | 0.86 | CYP3A4 (0.73) | CYP3A4SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL9050633 | 0.85 | SIGMAR1 (0.84) | CYP3A4SLC6A2SLC6A4SLC6A3CYP1A2 | |
| Difencloxazine SCHEMBL29710921 | 0.85 | SLC6A2 (0.76) | CYP3A4SLC6A2SLC6A4SLC6A3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11722 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724114-A1 | CYANOACRYLATE ADHESIVE KITS | Chemence, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| WO-2026041855-A1 | CYANOACRYLATE ADHESIVE KITS | CHEMENCE, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| US-12409173-B2 | Repurposing FDA-approved drugs as a novel cancer therapeutic avenue through inhibition of PRMT5 | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-09-09 | — | — | US | claimed |
| US-20230346761-A1 | REPURPOSING FDA-APPROVED DRUGS AS A NOVEL CANCER THERAPEUTIC AVENUE THROUGH INHIBITION OF PRMT5 | NATIONAL INSTITUTES OF HEALTH | 2023-11-02 | — | — | US | claimed |
| CN-115598261-A | Method for determining hydrochloride cloperastine raw material and related substances in preparation thereof | 地奥集团成都药业股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| EP-4084871-A1 | REPURPOSING FDA-APPROVED DRUGS AS A NOVEL CANCER THERAPEUTIC AVENUE THROUGH INHIBITION OF PRMT5 | The Trustees of Indiana University (US) | 2022-11-09 | — | — | EP | claimed |
| WO-2021138578-A1 | REPURPOSING FDA-APPROVED DRUGS AS A NOVEL CANCER THERAPEUTIC AVENUE THROUGH INHIBITION OF PRMT5 | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2021-07-08 | — | — | WO | claimed |
| CN-112755034-A | Production process of compound paracetamol, caffeine and pseudoephedrine capsules | 四川诺远药业有限公司 | 2021-05-07 | — | — | CN | claimed |
| US-20200411314-A1 | Diamond Seed Technology | HAMILTON & EADES GENETIC RESEARCH and DEVELOPMENT, LLC (US) | 2020-12-31 | — | — | US | claimed |
| CN-1314999-A | Modulation of multiple lineage kinase proteins | CEPHALON INC (US) | 2001-09-26 | — | — | CN | claimed |
| EP-0664118-B1 | SUSTAINED-RELEASE TABLET | YOSHITOMI PHARMACEUTICAL (JP) | 1999-08-25 | — | — | EP | claimed |
| EP-0894794-A1 | Optical isomers of cloperastine | AESCULAPIUS FARMACEUTICI S.r.l. (IT) | 1999-02-03 | — | — | EP | claimed |
| US-5593694-A | FILMS FOR TABLETS FROM ETHYL CELLULOSE AND ACETYL CELLULOSE IN SOLVENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-01-14 | — | — | US | claimed |
| EP-0582380-B1 | Dry granulation using a fluidized bed | MCNEIL PPC INC (US) | 1996-09-04 | — | — | EP | claimed |
| US-5492127-A | Method of using a diagnostic apparatus for functional examination of a human circulatory organ system | SONY CORPORATION (JP) | 1996-02-20 | — | — | US | claimed |
| US-5429825-A | Mixing a powdered drug and excipients in a fluidized bed with countercurrent flow of gas and rotation | MCNEIL-PPC, INC. (US) | 1995-07-04 | — | — | US | claimed |
| EP-0582380-A1 | Dry granulation using a fluidized bed | McNEIL-PPC, INC. (US) | 1994-02-09 | — | — | EP | claimed |
| EP-0415010-A1 | Diagnostic apparatus for functional examination of circulatory organ system | SONY CORPORATION (JP) | 1991-03-06 | — | — | EP | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |